July 13, 2026
Oncolytics Biotech Reports FDA Milestone and Strong Clinical Progress in RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech is preparing for an FDA Type D meeting to discuss a potential registrational pathway for pelareorep while rapidly activating clinical sites for its randomized REO 033 colorectal cancer trial.
